Low-dose arabinosyl cytosine therapy of AML may be effective after failure of high or conventional doses.
In 3 patients with ANLL, chemotherapy including high or conventional doses of Ara-C had been ineffective. However subsequent treatment with low-dose (LD) Ara-C induced a PR or CR which were sustained with regular LD Ara-C reinduction courses. Survival of the 2 patients with PR was 24 and 8 months respectively. The patient with CR was alive 18 months after a bone marrow graft. In 2/3 cases, the cytogenetic abnormalities initially detected disappeared with treatment. These observations suggest that the cellular mechanism of action of LD Ara-C is different from that of HD Ara-C, but do not favour a differentiating action of LD Ara-C. LD Ara-C can be prescribed as a salvage therapy even after failure of high or conventional doses.
Tertian
G
G
Laboratoires d'Hématologie et de Cytogénétique, Hôpital Antoine Béclère, Clamart, France.
Tchernia
G
G
Léonard
C
C
Miélot
F
F
Avalos
M
M
Mirica
C
C
Brivet
F
F
Dommergues
J P
JP
D000328:Adult; D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation; D002648:Child; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012074:Remission Induction
D003561:Cytarabine